Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05762900

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

35 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, 100021, China

Location status: Recruiting

Location contact

Hao Jing, M.D.

CONTACT

[email protected]

8610-87788281

About this study

During the study, the patients would undergo radiation of 5.2Gy for 5 fractions to the prophylactic radiation volumes and and a 6Gy per-fraction simultaneous boost to the tumor bed or other high-risk volumes. Acute toxicity of grade 2 or higher in the following 12 weeks after radiotherapy is the primary end point.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with invasive or non-invasive breast cancer;
  • The patients have undergone breast-conserving surgery or mastectomy with axillary sentinel nodal biopsy or dissection;
  • Stage ypT0-2N0-1 (if receive neoadjuvant therapy) or stage pT0-2N0-1 (if receive upfront surgery).
  • No distant metastasis;
  • Life expectancy ≥6 months;
  • Organ function is fine (Hemoglobin ≥100g/L, leukocyte ≥2×109/L, neutrophil ≥1×109/L, platelet ≥80×109/L; Creatinine 1.5 mg/dl or less; Alanine aminotransferase/aspartate aminotransferase ≤2.5×UNL.);
  • Patients are willing to cooperate to follow up;
  • Patients should sign the informed consent;
  • Women of childbearing age need effective contraception.

Exclusion criteria

  • Biopsy proven ipsilateral supraclavicular, infraclavicular or internal mammary nodal involvement.
  • Concurrent or previous neuropathy overlapping with the radiation volume or brachial plexus injury;
  • Patients who had radiotherapy to the ipsilateral breast, lymph-drainage regions or adjacent areas before;
  • Concurrent active connective tissue disease;
  • Other malignancies, which affect patient life expectancy (except adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder neoplasms (no more than T1), early stage thyroid carcinoma);
  • Severe comorbidities or active disease (Poorly controlled heart disease: New York Classification of Cardiac Function ≥ Grade 2, active coronary heart disease, unstable angina pectoris, arrhythmia requiring medical treatment/persistent refractory hypertension; Myocardial infarction, stroke within six months; Poorly controlled diabetes persists. Fasting blood glucose ≥ 10mmol/L, 2 hours postprandial blood glucose ≥ 13 mmol/L. Poorly controlled psychosis develops or worsens within six months; Active infection; Positive for antibodies to HIV).
  • Pregnant or breast-feeding.

Treatment and study plan

Ultra-fractionated radiation therapy

Radiation

5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.

Other names: Simultaneous Integrated Boost

Primary outcomes

  1. The rate of patients who develop radiation-associated acute toxicity (≥ 2 degree)

    Time frame: until 12 weeks from the completion of postoperative radiotherapy

    The investigators will record the incidence of ≥ 2 degree radiation-associated acute toxicity, such as breast or chest wall oedema, acute dermatitis, breast pain,itch of breast skin; ≥ 3 degree radiation-associated esophagitis; ≥ 3 degree radiation-associated lymphopenia.

Secondary outcomes

  1. Local recurrence rate

    Time frame: Local recurrence rate would be recorded and reported until at least 5 years after diagnosis.

    The incidence of recurrence of any invasive or non-invasive breast cancer in the ipsilateral breast or chest wall.

  2. Local regional recurrence rate

    Time frame: Local regional recurrence rate would be recorded and reported until at least 5 years after diagnosis.

    The incidence of recurrence in the ipsilateral breast/chest wall or the lymphatic nodal regions.

  3. Disease-free survival

    Time frame: Until at least 5 years after diagnosis.

    The time interval from diagnosis to any event of recurrence or death.

  4. Overall survival

    Time frame: Until at least 5 years after diagnosis.

    The time interval from diagnosis to death from any reason.

  5. The rate of patients who develop radiation-associated long-term toxicity

    Time frame: From 12 weeks to 5 years post radiotherapy.

    The investigators will record the incidence of any long-term toxicities, such as skin or subcutaneous fibrosis, pain, breast distortion, brachial plexopathy, lymphodema, cardiac event, rib fracture, pulmonary fibrosis, and so on.

  6. Quality of Life.

    Time frame: European Organization Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire EORTC QLQ-C30 to record patients' quality of life before and at 12, 24 and 60 months after radiotherapy.

    European Organization for Research and Treatment of Cancer General Quality of Life Questionnaire (brev: EORTC C-30) is used. The higher the score, the worse the situation, with the range of 28 to 112.

  7. Quality of Life.

    Time frame: The patients' quality of life will be evaluated before and at 12, 24 and 60 months after radiotherapy.

    European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (brev: EORTC BR-23) is used. The higher the score, the worse the situation, with the range of 23 to 92.

  8. The cosmetic outcome.

    Time frame: The cosmetic outcome will be evaluated before and at 12, 24 and 60 months after radiotherapy.

    Breast Cancer Treatment Outcome Scale 22 (brev: BCTOS 22) is used, for patients who receive breast conservative surgery. The higher the score, the worse the cosmesis, with the range of 22 to 88.

Study contacts

Contact information is provided by the study sponsor or research team.

Shu-Lian Wang, M.D.

CONTACT

[email protected]

8610-87788290

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Official study title

Ultra-hypofractioNated Radiotherapy ± sImultaneous Integrated Boost for Low-risk(risQue) Breast Cancer Patients After Breast Conservative sUrgery or mastEctomy (UNIQUE)

Acronym: UNIQUE

Important dates

Study start
2022
Primary completion
2025
Study completion
2030
First posted
Mar 10, 2023
Registry last updated
Mar 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.